<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05099640</url>
  </required_header>
  <id_info>
    <org_study_id>PTC923-MD-003-PKU</org_study_id>
    <secondary_id>2021-000474-29</secondary_id>
    <nct_id>NCT05099640</nct_id>
  </id_info>
  <brief_title>A Study of PTC923 in Participants With Phenylketonuria</brief_title>
  <official_title>A Phase 3 Study of PTC923 in Subjects With Phenylketonuria</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PTC Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>PTC Therapeutics</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this trial is to evaluate the efficacy of PTC923 in reducing blood&#xD;
      phenylalanine (Phe) levels in participants with phenylketonuria as measured by mean change in&#xD;
      blood Phe levels from baseline to Weeks 5 and 6 (that is, the average of each respective&#xD;
      treatment dose 2-week period of double-blind treatment).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study includes 2 parts: Part 1 and 2. Part 1 of the study tests for responsiveness to&#xD;
      PTC923, with 14 days of open-label treatment with PTC923. At the end of treatment in Part 1,&#xD;
      the mean change in blood Phe levels over the 14-day treatment period for all participants&#xD;
      will be assessed against their pretreatment (baseline) blood Phe level. Participants ≥2 years&#xD;
      of age who experience a &lt;15% reduction in blood Phe levels will be classified as&#xD;
      non-responsive and participation in the study will be terminated. Participants (≥2 years of&#xD;
      age) who experience a ≥15% reduction in blood Phe levels will continue into Part 2.&#xD;
      Participants &lt;2 years of age who experience ≥30% reduction in blood Phe levels will be&#xD;
      offered the option to enroll directly into an open-label extension Study PTC923-MD-004-PKU.&#xD;
      Following the minimum 14-day PTC923 washout period, all eligible participants will be&#xD;
      randomized in Part 2 to receive either PTC923 or placebo. After 6 weeks of treatment with&#xD;
      either PTC923 or placebo, participants will be offered the option to enter an open-label&#xD;
      extension Study PTC923-MD-004-PKU.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 30, 2021</start_date>
  <completion_date type="Anticipated">February 9, 2023</completion_date>
  <primary_completion_date type="Anticipated">February 9, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Phe Levels at Part 2 Weeks 5 and 6</measure>
    <time_frame>Baseline, Weeks 5 and 6 (average of the 2-week period)</time_frame>
    <description>Baseline blood Phe level will be the mean of Day -1 and Day 1 (predose) blood Phe levels.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Baseline Phe Levels ≥600 micromoles (μmol)/liter (L) who Achieved Phe Levels &lt;600 μmol/L at the End of the Double-Blind Treatment Period</measure>
    <time_frame>Baseline to Week 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mean Blood Phe Levels at Each PTC923 Dose Level (Average of the Each 2-Week Period in Part 2)</measure>
    <time_frame>Baseline, Weeks 1 and 2, Weeks 3 and 4, and Weeks 5 and 6</time_frame>
    <description>Baseline blood Phe level will be the mean of Day -1 and Day 1 (predose) blood Phe levels.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">178</enrollment>
  <condition>Phenylketonuria</condition>
  <arm_group>
    <arm_group_label>Part 1: PTC923</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive PTC923 7.5 milligrams (mg)/kilogram (kg (participants 0 to &lt;6 months of age), 15 mg/kg (participants 6 to &lt;12 months of age), 30 mg/kg (participants 12 months to &lt;2 years of age), or 60 mg/kg (participants ≥2 years of age) orally once daily for 14 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: PTC923</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive PTC923 20 mg/kg daily for Weeks 1 and 2, then PTC923 40 mg/kg daily for Weeks 3 and 4, then PTC923 60 mg/kg daily for Weeks 5 and 6.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive equivalent quantities of placebo to match the 20 to 40 to 60 mg/kg dose escalation of the PTC923 treatment arm.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PTC923</intervention_name>
    <description>PTC923 powder for oral use will be suspended in water or apple juice prior to administration.</description>
    <arm_group_label>Part 1: PTC923</arm_group_label>
    <arm_group_label>Part 2: PTC923</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo matching to PTC923</description>
    <arm_group_label>Part 2: Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Blood Phe level ≥360 μmol/L anytime during screening, or blood Phe level ≥360 μmol/L&#xD;
             when taking the average of the 3 most recent Phe levels from the participant's medical&#xD;
             history (inclusive of the screening value).&#xD;
&#xD;
          -  Clinical diagnosis of phenylketonuria with hyperphenylalaninemia (HPA) documented by&#xD;
             past medical history of at least 2 blood Phe measurements ≥600 μmol/L.&#xD;
&#xD;
          -  Women of childbearing potential must have a negative pregnancy test at screening and&#xD;
             agree to abstinence or the use of at least one highly effective form of contraception&#xD;
             for the duration of the study, and for up to 30 days after the last dose of study&#xD;
             drug.&#xD;
&#xD;
          -  Males who are sexually active with women of childbearing potential who have not had a&#xD;
             vasectomy must agree to use a barrier method of birth control during the study and for&#xD;
             up to 90 days after the last dose of study drug. Males must also refrain from sperm&#xD;
             donations during this time period.&#xD;
&#xD;
          -  Willing to continue current diet unchanged while participating in the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Gastrointestinal disease (such as irritable bowel syndrome, inflammatory bowel&#xD;
             disease, chronic gastritis, and peptic ulcer disease, etc.) that could affect the&#xD;
             absorption of study drug.&#xD;
&#xD;
          -  History of gastric surgery, including Roux-en-Y gastric bypass surgery or an&#xD;
             antrectomy with vagotomy, or gastrectomy.&#xD;
&#xD;
          -  History of allergies or adverse reactions to synthetic tetrahydrobiopterin (BH4) or&#xD;
             sepiapterin.&#xD;
&#xD;
          -  Current participation in any other investigational drug study or use of any&#xD;
             investigational agent within 30 days prior to screening.&#xD;
&#xD;
          -  Any clinically significant laboratory abnormality as determined by the investigator.&#xD;
&#xD;
          -  A female who is pregnant or breastfeeding, or considering pregnancy.&#xD;
&#xD;
          -  Serious neuropsychiatric illness (for example, major depression) not currently under&#xD;
             medical control, that in the opinion of the investigator or sponsor, would interfere&#xD;
             with the participant's ability to participate in the study or increase the risk of&#xD;
             participation for that participant.&#xD;
&#xD;
          -  Past medical history and/or evidence of renal impairment and/or condition including&#xD;
             moderate/severe renal insufficiency (glomerular filtration rate [GFR] &lt;60 milliliters&#xD;
             [mL]/minute [min]) and/or under care of a nephrologist.&#xD;
&#xD;
          -  Any abnormal physical examination and/or laboratory findings indicative of signs or&#xD;
             symptoms of renal disease, including calculated GFR &lt;60 mL/min/1.73 square meter&#xD;
             (m^2).&#xD;
&#xD;
          -  Requirement for concomitant treatment with any drug known to inhibit folate synthesis&#xD;
             (for example, methotrexate).&#xD;
&#xD;
          -  Clinical diagnosis of a primary BH4 deficiency.&#xD;
&#xD;
          -  Major surgery within the prior 90 days of screening.&#xD;
&#xD;
          -  Concomitant treatment with BH4 supplementation (for example, sapropterin&#xD;
             dihydrochloride, KUVAN) or pegvaliase-pqpz (PALYNZIQ).&#xD;
&#xD;
          -  Unwillingness to washout from BH4 supplementation (for example, sapropterin&#xD;
             dihydrochloride, KUVAN) or pegvaliase-pqpz (PALYNZIQ)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Patient Advocacy</last_name>
    <phone>1-866-562-4620</phone>
    <email>medinfo@ptcbio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Colorado and the Children's Hospital CO</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Janet Thomas</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UF College of Medicine, Department of Pediatrics Division of Genetics and Metabolism</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32608</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Roberto Zori</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Indiana University School of Medicine</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Melissa Lah</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Boston Children's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Stephanie Sacharow</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai (ISMMS)</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>01009</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>George Diaz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UPMC Children's Hospital of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Gerald Vockley</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Medical Center Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Markey McNutt</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas Health Science Center of Texas</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Hope Northrup</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Utah, Division of Medical Genetics (pediatric and adult clinic)</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Nichola Longo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Donald Basel</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital at Westmead</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Katherine Lewis</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Westmead Hospital</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Michel Tchan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>PARC Clinical Research</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>SA 5000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Drago Bratkovic</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Presidente Vargas</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande Do Sul</state>
        <zip>90035-074</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Paula Vargas</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de clinicas de Porto Alegre</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande Do Sul</state>
        <zip>90035-903</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Ida Schwartz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo</name>
      <address>
        <city>Ribeirão Preto</city>
        <state>São Paulo</state>
        <zip>14051-140</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Maria Avanise Yumi Minami</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Metabolics and Genetics in Calgary (MAGIC) Clinic, Ltd.</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>AB T2M 0L6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Aneal Khan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Hospital for Sick Children University of Toronto, Adult Clinic: The Fred A Litwin Family Centre in Genetic Medicine University Health Network &amp; Mt. Sinai Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1X8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Neal Sondheimer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Copenhagen University Hospital, Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>DK-2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Allan Lund</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bretonneau Hospital - CHRU de Tours</name>
      <address>
        <city>Tours</city>
        <state>Centre-Val De Loire</state>
        <zip>37000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Adrien Bigot</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU de Tours- Hôpital Pédiatrique de Clocheville</name>
      <address>
        <city>Tours</city>
        <state>Centre-Val De Loire</state>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Francois Labarthe</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pediatric Surgery Center</name>
      <address>
        <city>Tbilisi</city>
        <zip>159</zip>
        <country>Georgia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Lali Margvelashvili</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Children's Hospital Hamburg Eppendorf (Kinder-UKE)</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Ania Carolina Muntau</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Münster</name>
      <address>
        <city>Münster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Frank Rutsch</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Policlinico Umberto I</name>
      <address>
        <city>Rome</city>
        <state>Lazio</state>
        <zip>00185</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Vincenzo Leuzzi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Division of Inherited Metabolic Diseases, Azienda Ospedaliera-Università Padova</name>
      <address>
        <city>Padua</city>
        <state>Veneto</state>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Alberto Burlina</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>PanAmerican Clinical Research</name>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <zip>44670</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Ixiu del Carmen Cabrales Guerra</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Grupo Médico Camino SC</name>
      <address>
        <city>Benito Juarez</city>
        <state>Mexico City</state>
        <zip>3310</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Mara Medeiros Domingo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UMCG Beatrix Children's Hospital</name>
      <address>
        <city>Groningen</city>
        <zip>9713 GZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Francjan Van Spronsen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centro Hospitalar Universitário Do Porto, Epe</name>
      <address>
        <city>Porto</city>
        <state>Douro Litoral</state>
        <zip>4099-001</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Esmeralda Martins</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CENTRO HOSPITALAR UNIVERSITÁRIO LISBOA NORTE Hospital de Santa Maria,</name>
      <address>
        <city>Lisboa</city>
        <state>Estremadura</state>
        <zip>1649-035</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Patricia Janeiro</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CENTRO HOSPITALAR UNIVERSITÁRIO LISBOA NORTE Hospital de Santa Maria</name>
      <address>
        <city>Lisboa</city>
        <state>Estremadura</state>
        <zip>1649-035</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Anabela Oliveira</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Sant Joan de Déu</name>
      <address>
        <city>Barcelona</city>
        <state>Esplugues De Llobregat</state>
        <zip>8950</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Jaume Campistol</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Ramón y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Amaya Belanger-Quintana</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hacettepe University Medical Faculty</name>
      <address>
        <city>Altındağ</city>
        <state>Ankara</state>
        <zip>6230</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Serap Sivri</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gazi University Medical Faculty</name>
      <address>
        <city>Yenimahalle</city>
        <state>Ankara</state>
        <zip>6560</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Faith Ezgu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istanbul University</name>
      <address>
        <city>Fatih</city>
        <state>Istanbul</state>
        <zip>34098</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Ertugrul Kiykim</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ege University Faculty of Medicine Children Hospital</name>
      <address>
        <city>Bornova</city>
        <state>Izmir</state>
        <zip>35100</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Ebru Canda</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cukurova Üniversity Balcali Hospital Health Application and Research Center</name>
      <address>
        <city>Adana</city>
        <zip>1130</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Neslihan Mungan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Birmingham Children's Hospital NHS Foundation Trust</name>
      <address>
        <city>Birmingham</city>
        <zip>B4 6DH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Suresh Vijay</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Great Ormond Street Hospital</name>
      <address>
        <city>London</city>
        <zip>WC1N 3JH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Anupam Chakrapani</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Georgia</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Mexico</country>
    <country>Netherlands</country>
    <country>Portugal</country>
    <country>Spain</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 6, 2021</study_first_submitted>
  <study_first_submitted_qc>October 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 29, 2021</study_first_posted>
  <last_update_submitted>October 18, 2021</last_update_submitted>
  <last_update_submitted_qc>October 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Phenylketonurias</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

